Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, with the aim of expanding its position in the gene therapy space for the treatment of inherited retinal diseases, according to a press release.
The company will operate under the name Opus Genetics and will trade on Nasdaq under the ticker symbol “IRD” beginning Oct. 24.
The company’s most advanced gene therapy candidate, OPGx-LCA5 for the treatment of Leber congenital amaurosis, demonstrated visual improvement in three out of three adult patients with late-stage disease at 6 months in an open-label,